Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients

被引：50

作者：

Jurczyszyn, Artur ^{[1
]}

Radocha, Jakub ^{[2
]}

Davila, Julio ^{[3
]}

Fiala, Mark A. ^{[4
]}

Gozzetti, Alessandro ^{[5
]}

Grzasko, Norbert ^{[6
,7
]}

Robak, Pawel ^{[8
]}

Hus, Iwona ^{[9
]}

Waszczuk-Gajda, Anna ^{[10
]}

Guzicka-Kazimierczak, Renata ^{[11
]}

Atilla, Erden ^{[12
,13
]}

Mele, Giuseppe ^{[14
]}

Sawicki, Waldemar ^{[15
]}

Jayabalan, David S. ^{[16
]}

Charlinski, Grzegorz ^{[17
]}

Szabo, Agoston G. ^{[18
]}

Hajek, Roman ^{[19
,20
]}

Delforge, Michel ^{[21
]}

Kopacz, Agnieszka ^{[22
]}

Fantl, Dorotea ^{[23
]}

Waage, Anders ^{[24
]}

Avivi, Irit ^{[25
]}

Rodzaj, Marek ^{[26
]}

Leleu, Xavier ^{[27
]}

Richez, Valentine ^{[28
]}

Knopinska-Posluszny, Wanda ^{[28
]}

Masternak, Anna ^{[29
]}

Yee, Andrew J. ^{[30
]}

Barchnicka, Agnieszka ^{[31
]}

Druzd-Sitek, Agnieszka ^{[32
]}

Guerrero-Garcia, Thomas ^{[33
]}

Liu, Jieqi ^{[34
]}

Vesole, David H. ^{[35
]}

Castillo, Jorge J. ^{[36
]}

机构：

[1] Jagiellonian Univ, Coll Med, Krakow, Poland

[2] Charles Univ Hosp Hradec Kralove, Dept Med Haematol 4, Hradec Kralove, Czech Republic

[3] Hosp Univ Salamanca, Salamanca, Spain

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Le Scotte Hosp, Siena, Italy

[6] St Johns Canc Ctr, Dept Haematol, Lublin, Poland

[7] Med Univ Lublin, Dept Expt Haematol, Lublin, Poland

[8] Med Univ Lodz, Copernicus Mem Hosp, Dept Haematol, Lodz, Poland

[9] Med Univ Lublin, Dept Haematol & Bone Marrow Transplantat, Lublin, Poland

[10] Med Univ Warsaw, Dept Haematol Oncol & Internal Med, Warsaw, Poland

[11] Pomeranian Med Univ, Dept Haematol, Szczecin, Poland

[12] Ankara Univ, Haematol Dept, Sch Med, Ankara, Turkey

[13] Ankara Univ, Bone Marrow Transplantat Unit, Sch Med, Ankara, Turkey

[14] Osped A Perrino, Haemetaol, Brindisi, Italy

[15] Mil Inst Med, Dept Internal Med & Haematol, Warsaw, Poland

[16] Weill Cornell Med Coll, New York, NY USA

[17] Nicolaus Copernicus Hosp, Dept Haematol, Torun, Poland

[18] Dept Med, Sect Haematol, Vejle, Denmark

[19] Univ Hosp Ostrava, Ostrava, Czech Republic

[20] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[21] UZ Leuven, Dept Haematol, Leuven, Belgium

[22] Univ Rzeszow, Dept Haematol, Rzeszow, Poland

[23] Hosp Italiano Buenos Aires, Secc Hematol Adultos, Buenos Aires, DF, Argentina

[24] Norwegian Univ Sci & Technol, Trondheim, Norway

[25] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel

[26] State Hosp, Dept Haematol, Krakow, Poland

[27] CHU, Hop Mil, Serv Hematol, Poitiers, France

[28] Minist Interior Hosp Olsztyn, Warmia & Masuria Oncol Ctr, Olsztyn, Poland

[29] State Hosp, Dept Haematol, Opole, Poland

[30] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[31] Med Univ Silesia, Sch Publ Hlth Bytom, Dept Doctoral Studies, Katowice, Poland

[32] Maria Sklodowska Curie Inst, Oncol Ctr, Warsaw, Poland

[33] St Elizabeths Med Ctr, Dana Farber Canc Inst, Div Hematol & Oncol, Brighton, MA USA

[34] Rutgers New Jersey Med Sch, Newark, NJ USA

[35] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[36] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 180卷 / 06期

关键词：

myeloma; plasma cell leukaemia; therapeutic response; survival; prognosis; RESPONSE CRITERIA; MULTIPLE-MYELOMA; SINGLE-CENTER; BORTEZOMIB; TRANSPLANTATION; DEXAMETHASONE; SURVIVAL; LENALIDOMIDE; EXPERIENCE; IMPROVES;

D O I：

10.1111/bjh.15092

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report a multicentre retrospective study that analysed clinical characteristics and outcomes in 117 patients with primary plasma cell leukaemia (pPCL) treated at the participating institutions between January 2006 and December 2016. The median age at the time of pPCL diagnosis was 61years. Ninety-eight patients were treated with novel agents, with an overall response rate of 78%. Fifty-five patients (64%) patients underwent upfront autologous stem cell transplantation (ASCT). The median follow-up time was 50months (95% confidence interval [CI] 33; 76), with a median overall survival (OS) for the entire group of 23 months (95% CI 15; 34). The median OS time in patients who underwent upfront ASCT was 35 months (95% CI 24.3; 46) as compared to 13 months (95% CI 6.3; 35.8) in patients who did not receive ASCT (P=0.001). Multivariate analyses identified age >= 60years, platelet count <= 100x10(9)/l and peripheral blood plasma cell count >= 20x10(9)/l as independent predictors of worse survival. The median OS in patients with 0, 1 or 2-3 of these risk factors was 46, 27 and 12months, respectively (P<0.001). Our findings support the use of novel agents and ASCT as frontline treatment in patients with pPCL. The constructed prognostic score should be independently validated.

引用

页码：831 / 839

页数：9

共 28 条

[1] Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia
Benson, Don M., Jr.
Smith, Megan K.
[J]. LEUKEMIA & LYMPHOMA, 2007, 48 (07) : 1423 - 1425
[2] Thirty patients with primary plasma cell leukemia: a single center experience
Colovic, Milica
Jankovic, Gradimir
Suvajdzic, Nada
Milic, Natasa
Dordevic, Vesna
Jankovic, Snezana
[J]. MEDICAL ONCOLOGY, 2008, 25 (02) : 154 - 160
[3] Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party
D'Arena, G.
Valentini, C. G.
Pietrantuono, G.
Guariglia, R.
Martorelli, M. C.
Mansueto, G.
Villani, O.
Onofrillo, D.
Falcone, A.
Specchia, G.
Semenzato, G.
Di Renzo, N.
Mastrullo, L.
Venditti, A.
Ferrara, F.
Palumbo, A.
Pagano, L.
Musto, P.
[J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1499 - 1502
[4] Primary plasma cell leukemia and autologous stem cell transplantation
Drake, Mary B.
Iacobelli, Simona
van Biezen, Anja
Morris, Curly
Apperley, Jane F.
Niederwieser, Dietger
Bjorkstrand, Bo
Gahrton, Gosta
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (05): : 804 - 809
[5] International uniform response criteria for multiple myeloma
Durie, B. G. M.
Harousseau, J-L
Miguel, J. S.
Blade, J.
Barlogie, B.
Anderson, K.
Gertz, M.
Dimopoulos, M.
Westin, J.
Sonneveld, P.
Ludwig, H.
Gahrton, G.
Beksac, M.
Crowley, J.
Belch, A.
Boccadaro, M.
Turesson, I.
Joshua, D.
Vesole, D.
Kyle, R.
Alexanian, R.
Tricot, G.
Attal, M.
Merlini, G.
Powles, R.
Richardson, P.
Shimizu, K.
Tosi, P.
Morgan, G.
Rajkumar, S. V.
[J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
[6] Bortezomib is an efficient agent in plasma cell leukemias
Esparís-Ogando, A
Alegre, A
Aguado, B
Mateo, G
Gutiérrez, N
Bladé, J
Schenkein, D
Pandiella, A
San Miguel, JF
[J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 114 (04) : 665 - 667
[7] Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Fernandez de Larrea, C.
Kyle, R. A.
Durie, B. G. M.
Ludwig, H.
Usmani, S.
Vesole, D. H.
Hajek, R.
San Miguel, J. F.
Sezer, O.
Sonneveld, P.
Kumar, S. K.
Mahindra, A.
Comenzo, R.
Palumbo, A.
Mazumber, A.
Anderson, K. C.
Richardson, P. G.
Badros, A. Z.
Caers, J.
Cavo, M.
Leleu, X.
Dimopoulos, M. A.
Chim, C. S.
Schots, R.
Noeul, A.
Fantl, D.
Mellqvist, U-H
Landgren, O.
Chanan-Khan, A.
Moreau, P.
Fonseca, R.
Merlini, G.
Lahuerta, J. J.
Blade, J.
Orlowski, R. Z.
Shah, J. J.
[J]. LEUKEMIA, 2013, 27 (04) : 780 - 791
[8] Gluzinski A, 1907, POL ARCH NAUK BIOCH, V3, P181
[9] Gonsalves WI, 2017, AM J HEMATOL-ONCOL, V13, P21
[10] Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
Gonsalves, Wilson I.
Rajkumar, S. Vincent
Go, Ronald S.
Dispenzieri, Angela
Gupta, Vinay
Singh, Preet P.
Buadi, Francis K.
Lacy, Martha Q.
Kapoor, Prashant
Dingli, David
Lust, John A.
Zeldenrust, Steven R.
Hayman, Suzanne R.
Kyle, Robert A.
Gertz, Morie A.
Kumar, Shaji K.
[J]. BLOOD, 2014, 124 (06) : 907 - 912

← 1 2 3 →